Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study

Immune checkpoint inhibition has been demonstrated to be an effective anticancer strategy. Several lines of evidence support the study of immunotherapy in triple-negative breast cancer (TNBC). We assessed the safety and antitumor activity of the programmed cell death protein 1 (PD-1) inhibitor pembr...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of clinical oncology 2016-07, Vol.34 (21), p.2460-2467
Hauptverfasser:	Nanda, Rita, Chow, Laura Q M, Dees, E Claire, Berger, Raanan, Gupta, Shilpa, Geva, Ravit, Pusztai, Lajos, Pathiraja, Kumudu, Aktan, Gursel, Cheng, Jonathan D, Karantza, Vassiliki, Buisseret, Laurence
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Monoclonal, Humanized - therapeutic use Antineoplastic Agents - therapeutic use Female Humans L-Lactate Dehydrogenase - blood Middle Aged ORIGINAL REPORTS Triple Negative Breast Neoplasms - drug therapy Triple Negative Breast Neoplasms - mortality
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!